Business
HLS Therapeutics Appoints Christine Elliott to its Board of Directors
HLS Therapeutics Appoints Christine Elliott to its Board of Directors Canada NewsWire ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\n HLS Therapeutics Appoints Christine Elliott to its Board of Directors\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n TORONTO\n \n\n ,\n \n\n March 13, 2025\n \n\n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that\n \n Christine Elliott\n \n has been appointed to the Company's Board of Directors (the \"Board\"), effective immediately.\n \n\n Ms. Elliott served as\n \n Ontario's\n \n Deputy Premier and Minister of Health from 2018 to 2022, where she gained significant knowledge of, and experience with, the operation of\n \n Ontario's\n \n health system. From 2015 to 2018, she was appointed as\n \n Ontario's\n \n first Patient Ombudsman, advocating for patient rights and healthcare transparency. Prior to that, she was a member of the\n \n Ontario\n \n legislature from 2006-2015. In addition to her public service, Ms. Elliott currently serves as Counsel in the health group at Fasken Martineau DuMoulin LLP in\n \n Toronto\n \n .\n \n\n \"I am pleased to welcome Christine to our Board,\" said\n \n John Welborn\n \n , Chair of the Board at HLS. \"Her experience as\n \n Ontario's\n \n Minister of Health gives her a unique perspective on the Canadian healthcare landscape, from policy development to frontline patient care. Her understanding of regulatory and reimbursement frameworks will help HLS as we seek to expand access to existing therapies and bring new medicines to market, ultimately benefiting both patients and healthcare providers across\n \n Canada\n \n .\"\n \n\n \"I am honored to join the HLS Board,\" said\n \n Christine Elliott\n \n . \"Throughout my career in healthcare policy and public service, I've seen firsthand the importance of innovative therapies in improving patient outcomes. HLS's commitment to providing solutions that address unmet medical needs aligns with my passion for enhancing healthcare delivery, and I look forward to leveraging my exper...